Earnings call transcript: Castellum Q2 2026 revenue misses, shares sink 19%

Castellum (CTM) shares sank 19.34% to $0.6423 after reporting Q2 2026 EPS of -$0.01 on revenue of $13.9M, missing forecasts of +$0.01 EPS and $16.9M revenue (a -$3.0M, -17.8% revenue miss). Despite a positive first-half liquidity/operating cash flow turn (+$2.4M OCF vs -$2.3M prior year), gross margin narrowed to 34% from 36% as subcontractor mix increased and fixed-price work wound down. Management reiterated expectations for record 2026 full-year revenue supported by $271.7M backlog and guided conversion of at least 16% over the next 12 months (and ~48% over 24 months), but the near-term profitability profile (investment-year, lower EBITDA) remains a key headwind.

Analysis

The key issue is not demand collapse; it is that CTM is converting top-line visibility into earnings at a weaker rate than the market assumed. When a small contractor leans more on subcontracted work and fixed-price runoff, revenue can look “stable” while incremental margin compresses, which is exactly the wrong mix for a low-liquidity microcap that trades on operating leverage.

Second-order, backlog here is not the same as cashable revenue: government funding timing, option exercises, and task-order conversion can push recognition by months. That means the next catalyst is less about the headline pipeline and more about whether the company can show sequential margin recovery and sustained operating cash flow in the next 1-2 quarters; absent that, the market will treat the “investment year” framing as a euphemism for delayed EBITDA. If they do win or fund a meaningful Navy mod, the stock can gap violently, but the burden of proof is now much higher.

Contrarian view: the selloff may be larger than the fundamental damage because the balance sheet is clean and cash generation improved. But for a sub-$1 name, that only matters if management proves the revenue engine is scaling without permanent dilution to margins; otherwise the multiple stays hostage to execution risk. The thesis is falsified if CTM re-accelerates gross margin back above mid-30s with positive OCF and sequential backlog conversion over the next two quarters.

Key Decisions for Investors

• Avoid catching the knife in CTM after the post-earnings gap; wait 1-2 weeks for selling pressure to settle and for the stock to reclaim $0.70 before considering any long.
• If CTM rebounds into the $0.75-$0.80 area without a new funded award, fade the move with a tactical short; stop above $0.88 and target a retest of the prior low over 1-3 months.
• Pair trade: long quality defense exposure via ITA or LMT/NOC against a small short CTM position to express the spread between scaled primes and a microcap execution story over 1-3 months.
• Set a catalyst alert for the next quarter: if gross margin stays below 34% or operating cash flow turns negative again, maintain a bearish stance; if both improve, cover shorts immediately.
• Do not use options here unless liquidity is confirmed; the more efficient expression is a small cash-equity short or no trade.